Advertisements

Rapifen (Fentanyl)

Quick links to important sections

Rapifen (Fentanyl)

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Rapifen (Fentanyl)

Quick Facts

Property Description
Active ingredient Alfentanil (Alfentanil Hydrochloride)
Form Solution for intravenous injection
Pharmacological class Synthetic Opioid Analgesic
Common use Analgesic adjunct in general anesthesia
Origin Synthetic Phenylpiperidine derivative

What Type of Medicine is Rapifen (Alfentanil)?

Rapifen is a highly potent, injectable medication classified as a synthetic opioid analgesic primarily reserved for use in monitored clinical settings. Its core identity is rooted in its active pharmaceutical ingredient, Alfentanil, which is a chemically engineered compound belonging to the phenylpiperidinylpropanamide group, positioning it as a structural derivative of the broader Fentanyl class. This classification as a narcotic analgesic underscores its powerful ability to manage severe pain by working directly on the central nervous system. Alfentanil is noted for being less potent than Fentanyl, but features a substantially faster onset of action and a shorter duration. This characteristic makes it particularly advantageous for surgical procedures that require swift, fine-tuned control over the level of consciousness and analgesia.


Understanding Rapifen's General Role and Composition

The primary role of Rapifen is to serve as an indispensable supplement to general anesthesia, facilitating profound, controlled pain management and sedation during the immediate perioperative period. It is formulated as a single-ingredient product, typically delivered as a sterile, aqueous solution for injection intended exclusively for intravenous administration by healthcare professionals. Alfentanil is utilized as an analgesic supplement during various surgical procedures due to its fast onset. This means the medicine begins providing necessary pain relief almost immediately, allowing clinicians to maintain comfort swiftly. Alfentanil is additionally utilized as a primary anesthetic agent for the induction of anesthesia. This unique combination of high potency, rapid action, and controlled injectable form ensures the patient's stability and comfort are maintained during critical surgical procedures.

Regulatory References

  1. StatPearls - NIH
  2. StatPearls review from the NIH, Alfentanil is widely used as an analgesic supplement during various surgical procedures
Advertisements

What side effects are possible with Rapifen (Fentanyl)?

Possible side effects and safety information for Rapifen (Fentanyl)

Fentanyl, a potent opioid, has an officially documented safety profile characterized by the high potential for serious adverse reactions. The most significant risks are addressed by regulatory warnings, including the risks of Addiction, Abuse, and Misuse and Life-Threatening Respiratory Depression.

Key Adverse Reaction Categories

Adverse reactions typically involve the central nervous system, respiratory system, and gastrointestinal tract. Frequency classifications documented in regulatory sources (e.g., EMA/ICH frequency bands) include:

  • Very Common (ge 1 in 10): Nausea, vomiting, dizziness, and headache.
  • Common (ge 1 in 100 to < 1 in 10): Somnolence, constipation, hyperhidrosis (excessive sweating), and fatigue.

Serious and Clinically Significant Risks

Serious adverse reactions documented in official prescribing information include:

  • Life-threatening respiratory depression, which is the most dangerous risk and is dose-related, persisting longer than the analgesic effect.
  • Circulatory depression including severe hypotension and shock.
  • Serotonin Syndrome (when co-administered with serotonergic drugs).
  • Adrenal Insufficiency (a serious, though rare, condition associated with prolonged use).
  • Neonatal Opioid Withdrawal Syndrome (NOWS) resulting from prolonged use during pregnancy.

Population-Specific Safety Notes

Regulatory restrictions emphasize that the drug is contraindicated in opioid non-tolerant patients due to the fatal risk of respiratory depression. Caution is required for elderly or debilitated patients and those with chronic pulmonary, renal, or hepatic disease, as these groups are at increased risk of severe adverse events.

Safety-Related Limitations

Due to the significant risks, the product is subject to a restricted access program (e.g., TIRF REMS) for some formulations. Concomitant use with benzodiazepines or other CNS depressants (including alcohol) carries a regulatory Boxed Warning due to the risk of profound sedation, respiratory depression, coma, and death. Fatal overdose can also result from accidental exposure or the application of external heat to certain formulations, which increases absorption. Proper storage and disposal are strictly mandated to prevent accidental exposure, especially in children.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose with Rapifen (Fentanyl) as a serious, life-threatening, or fatal event primarily due to profound respiratory depression.

Documented Overdose Manifestations

The most significant clinical sign of overdose is apnea or severely depressed breathing, potentially leading to death. Other documented symptoms of a serious overdose include:

  • Central Nervous System (CNS) Depression: Stupor, marked sedation, or coma.
  • Muscle Rigidity: Severe rigidity of the skeletal muscles, which may involve the thoracic muscles, complicating breathing.
  • Skin Changes: Cold, clammy skin and cyanosis (bluish discoloration of the skin).
  • Cardiovascular Effects: Hypotension (low blood pressure) and bradycardia (slow heart rate), potentially progressing to cardiac arrest.

Required Emergency Response

Immediate medical attention is required upon any suspected or known overdose. The regulatory profile emphasizes that this is a medical emergency demanding rapid intervention.

Emergency management centers on establishing a patent airway and providing assisted or controlled ventilation. A specific opioid antagonist, such as naloxone, must be administered immediately. Because the duration of respiratory depression caused by fentanyl may exceed the action of the antagonist, repeated doses of naloxone and continuous medical surveillance are necessary until the risk of recurring respiratory depression has passed.

  • The risk of life-threatening respiratory depression is increased when Rapifen is used concurrently with other Central Nervous System depressants, including alcohol or benzodiazepines.
Advertisements

Therapeutic Uses of Rapifen (Fentanyl)

Rapifen (Fentanyl) Therapeutic Overview

Rapifen (Fentanyl) is utilized within medical settings to support the management of certain types of pain. Its approved therapeutic applications are centered on anesthesia and perioperative care, where it may serve as an analgesic agent with short duration of action.

Key uses include providing pain relief during the anesthetic periods, such as premedication, induction, and maintenance of anesthesia. The treatment is also suitable for managing pain in the immediate postoperative period, which takes place in the recovery room.

Additionally, Fentanyl is authorized for use as an analgesic supplement in both general and regional anesthesia protocols. The medication may also be used in combination with other agents for anesthetic premedication, induction, and maintenance. In selected patients undergoing complex procedures like open heart surgery, it may function as a primary anesthetic agent with oxygen.


Quick Facts: Main Therapeutic Domains

  • May help provide pain relief during the anesthetic periods.
  • Used for pain management in the immediate postoperative period.
  • Serves as an analgesic supplement in various anesthesia settings.
Advertisements

Eligibility and Restrictions for Use

Official Regulatory Eligibility and Restrictions for Rapifen (Alfentanil)

Rapifen (alfentanil) is a potent, short-acting opioid analgesic, structurally related to fentanyl, and its use is subject to strict governmental regulations. Official labeling defines who is eligible and who is prohibited from receiving this medication.

Eligibility Classification Population/Condition
Contraindicated Known hypersensitivity to alfentanil or other opioid analgesics.
Contraindicated Patients with obstructive airways disease or acute respiratory depression (if not being ventilated).
Contraindicated Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of cessation.
Contraindicated Administration during labour or Caesarean section prior to umbilical cord clamping.
Restricted Use/Caution Elderly and debilitated patients: A reduced initial dose is required.
Restricted Use/Caution Chronic liver or kidney disease: Dose reduction is recommended due to decreased clearance.
Not Recommended Children younger than one year, as safety and efficacy are not established.

Eligibility is primarily limited to adults and children over one year for use as an opioid analgesic adjunct during general anesthesia. The drug must be administered in a hospital setting by professionals trained in the management of potent opioids. Special caution is also warranted in patients who may be susceptible to respiratory depression, such as those with head injury, brain tumors, or decreased respiratory reserve.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The use of Rapifen (Fentanyl) with certain medicines or substances can lead to potentially life-threatening interactions due to both how the body processes the drug (pharmacokinetic) and its combined effect on the nervous system (pharmacodynamic).

High-Risk Combinations (Potential for Severe Side Effects)

Interacting Category Mechanism of Interaction Clinical Risk
CNS Depressants (e.g., Benzodiazepines, other sedatives, alcohol, general anesthetics) Potentiated Central Nervous System (CNS) depression Profound sedation, severe respiratory depression, coma, and death.
CYP3A4 Inhibitors (e.g., certain antibiotics, antifungal agents, protease inhibitors) Reduced clearance, leading to increased plasma concentration of Fentanyl Increased and prolonged opioid effects, including potentially fatal respiratory depression.
MAO Inhibitors (e.g., Phenelzine, Isocarboxazid) Severe, unpredictable potentiation (mechanism not fully defined) Contraindicated; use is not recommended within 14 days of taking an MAO Inhibitor.
Serotonergic Drugs (e.g., certain antidepressants) Additive effect on serotonin levels Risk of Serotonin Syndrome, a potentially life-threatening condition.

Other Significant Interactions

Medicines that are CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine) can decrease Fentanyl levels, potentially leading to reduced pain relief or withdrawal symptoms. Conversely, discontinuing an inducer may increase Fentanyl concentration. Mixed Agonist/Antagonist Opioids (e.g., Pentazocine) are not recommended as they may reduce Fentanyl's effect or precipitate withdrawal. Individuals should discuss all prescription, non-prescription, and herbal products, especially St. John’s wort and grapefruit juice, with a healthcare provider.

Advertisements

Mechanism of Action

The mechanism of Rapifen (Fentanyl) centers on its interaction with the central nervous system (CNS). Fentanyl functions as a selective agonist at the mu-opioid receptor (MOR), a G protein-coupled receptor expressed on neuronal membranes, particularly within circuits involved in nociception pathways. The agonist binding to the MOR activates the inhibitory G-protein ( Gi). This activation initiates an intracellular signaling cascade that involves the inhibition of adenylyl cyclase (AC), thereby decreasing the intracellular concentration of cyclic AMP (cAMP). Concurrently, the cascade modulates ion channel activity by promoting the opening of specific inward-rectifying mathrmK^+ channels and the closing of voltage-gated mathrmCa^2+ channels. These combined effects cause the hyperpolarization of the neuronal membrane. This increased membrane negativity reduces the cell's excitability and results in a reduction of neurotransmitter release from pre-synaptic nerve terminals, which constitutes the pharmacological basis of the drug's activity.

Advertisements

Dosage and Administration Information

Administration Overview for Rapifen Injection

Rapifen (alfentanil) is a potent, short-acting opioid analgesic, structurally related to fentanyl, and is administered strictly in a hospital setting for perioperative use. Its administration requires the presence of personnel specially trained in the use of intravenous anesthetics and management of opioid respiratory effects, as well as readily available resuscitation equipment.

Administration Scope Details
Route of Administration Intravenous (IV) injection or continuous IV infusion.
Dosing Principle Dosage must be individualized based on the patient's physical status, age, weight, and the duration and nature of the surgical procedure.
Preparation May be diluted for infusion using 0.9% sodium chloride, 5.0% glucose injection, or compound sodium lactate injection (Ringer Lactate). Diluted solutions should be used within 24 hours of preparation.
IV Bolus Administration Initial doses should be administered slowly, often over 30 seconds to 3 minutes, to mitigate risks such as truncal rigidity.
Age-Specific Use Elderly/Debilitated patients require a reduced initial dose. Use in children under one year has not been established, but for children aged one year and older, the dose must be carefully titrated and may require a higher or more frequent infusion rate than in adults due to a shorter half-life.
Frequency/Timing Administered as-needed (PRN) during the anesthetic period, or by continuous infusion, with the last infusion or incremental dose typically discontinued 5 to 10 minutes before the end of surgery to aid recovery.

Procedural Constraints: The total dose of all opioid agonists must be considered by the practitioner. Patients must be continuously monitored for respiratory effects during and after administration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rapifen (Fentanyl)

1. Evidence for use as an Analgesic Component of Anesthesia

Rapifen (Fentanyl) was studied for its use as an analgesic component during general anesthesia for brief procedures. The research primarily consisted of short-term Randomized Controlled Trials (RCTs) and systematic reviews, which examined its use during the induction (starting) and maintenance phases of anesthesia. Researchers monitored specific outcomes related to the onset speed and duration of measured changes, the stability of intraoperative physiological measures, and the amount of other anesthetic medications administered.

The findings describe patterns observed in the studies where Rapifen was associated with a rapid onset of measured changes related to acute pain in the perioperative setting. Research highlights changes measured during the study period and described patterns indicating that the use of Rapifen was studied alongside a lower co-administered dose of other general anesthetic agents. However, the reported outcomes were consistently short-term, limited to the time the patient was under anesthesia and the immediate transfer to the recovery area.

2. Evidence for Short-Duration Pain Management in Recovery

Studies also explored Rapifen's use for managing acute pain immediately after surgery. The research included placebo-controlled trials. These studies monitored specific patient-reported outcomes describing perceived discomfort by measuring post-operative pain intensity scores and observing the time until patients requested supplemental pain medication.

Research describes that in the studied populations, the administration of Rapifen was observed in some studies to be associated with reported measurements that included low post-operative pain scores during the immediate recovery period. Some trials described patterns in which the time elapsed before patients requested supplemental pain relief was different compared to groups that received a placebo-control. However, the observed changes in pain-related measures were brief, consistent with the drug's short action.

3. Long-Term Outcomes and Follow-up Data

Studies focusing on outcomes related to physical discomfort or functional measures were evaluated in research for only very short durations. The current research landscape appears to focus almost exclusively on effects observed during and immediately after the surgical procedure. There is limited information for long-term outcomes that may involve recovery milestones or continued functional improvement following a single administration during anesthesia.

4. Evidence in Special Patient Groups

Rapifen was evaluated in studies that included pediatric patients (children) and older adult populations. Research explored whether similar patterns of short-term response was observed in these groups as in the general adult population. Specific trials examined its performance in populations with certain pre-existing conditions, such as cardiovascular disease, to examine its performance in patients whose health status involves periods of heightened symptoms or physiological changes.

However, data for certain groups remain insufficient. The sample sizes were modest for many of these subgroup analyses, meaning the certainty of the findings remains low. Subgroup findings are uncertain when trying to generalize these results to all patients with similar co-morbidities.

5. What is Still Uncertain About Rapifen (Fentanyl) Research

Long-term effects are not fully established, particularly concerning patient recovery and well-being after hospital discharge. Evidence is limited for many special populations, meaning that research does not determine whether an individual will respond similarly if they fall outside the specific characteristics of the studied groups. The data show patterns related to rapid, short-term changes, but the studies provide limited information about the duration of these effects. Research focusing on these evidence gaps is still required to provide more context and understanding.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Rapifen (Fentanyl) (FAQ)

Q: How quickly does Rapifen start working?

Regulatory documents state that Rapifen has a rapid or immediate onset of action for its pain-relieving effects. This rapid action is one of the key characteristics described in the official product information for its use during medical procedures.

Q: How long does the effect of Rapifen last?

Rapifen is officially described as a short-acting opioid analgesic. The official product information notes that the main analgesic effect lasts only a brief duration after it is administered.

Q: Can Rapifen cause breathing problems?

Official warnings state that a serious, life-threatening, or fatal reduction in breathing, known as respiratory depression, is the most significant risk associated with Rapifen. This adverse effect is described as being dose-related and may be observed for a period that extends beyond the time of its analgesic effect.

Q: Does Rapifen cause drowsiness or make you sleepy?

Official safety documents indicate that drowsiness (somnolence) is listed as a common side effect of Rapifen. This potential for reduced alertness is why regulatory cautions exist regarding activities like driving after administration.

Q: Is it normal to feel dizzy after receiving Rapifen?

Official safety information lists dizziness as a very common side effect, which means it has been reported in a significant portion of the patient population studied. Patients are typically monitored for this effect during and after administration.

Q: Can Rapifen be used for chronic pain outside of a hospital setting?

Because official prescribing information states that Rapifen injection is administered strictly in a hospital setting for perioperative and intensive care use, it is not used for managing long-term pain in non-clinical settings.

Q: Is Rapifen considered a strong pain reliever?

Yes, Rapifen is officially described in regulatory documents as a potent opioid analgesic. This potency is a key factor in its use during specialized medical procedures where rapid, strong pain relief is required.

Q: What is the risk of dependence or addiction with Rapifen?

Official warnings state that Rapifen poses risks of addiction, abuse, and misuse. The development of physical or psychological dependence can occur, even when the drug is used appropriately as prescribed.

Q: Are there any foods or drinks that should be avoided with Rapifen?

Official documents strongly advise against the co-administration of alcohol due to the increased risk of dangerous side effects, including severe respiratory depression. Additionally, the consumption of grapefruit juice has been noted to potentially increase the concentration of the drug in the body.

Q: Is Rapifen usage different for children than for adults?

Official labels state Rapifen is indicated for use in a range of pediatric patients, including neonates, infants, children, and adolescents, associated with general anesthesia. Regulatory instructions describe that the dosage must be adjusted and carefully titrated based on the child's age and clinical status.

Q: Is there a maximum time someone can be given Rapifen?

Rapifen is used for short-duration procedures. Official instructions state that for continuous infusion, the last incremental dose or infusion is typically discontinued 5 to 10 minutes before the end of surgery to allow for patient recovery.

Q: How does Rapifen affect heart rate?

Official prescribing information lists bradycardia (a slow heart rate) and sometimes other cardiac rhythm changes as potential adverse effects. For this reason, continuous monitoring of the patient's heart rate is a standard measure when the medication is being administered.

Q: Can Rapifen cause allergic reactions?

Rapifen is officially contraindicated (should not be used) in patients with a known allergy or hypersensitivity to the active ingredient, alfentanil hydrochloride, any of its components, or other strong opioid analgesics.

Q: Can Rapifen affect your mood?

Official safety data indicates that Rapifen can cause alterations in mood, which are described as commonly occurring. These changes may include feelings of pleasure (euphoria) or a general feeling of unease or dissatisfaction (dysphoria).

Q: Is Rapifen used to help people relax before a procedure?

Rapifen is primarily indicated as an analgesic (pain-relieving) component of general anesthesia. Its use alongside other sedating drugs, such as those that might reduce anxiety, is done with extreme caution due to the high risk of profound sedation.

Q: What is the risk of overdose associated with Rapifen?

Official warnings state that due to the potency of the drug, misuse or accidental exposure to Rapifen can result in a life-threatening overdose and potentially lead to death.

Q: Is there an antidote or reversal agent for Rapifen effects?

Yes, the respiratory depression caused by Rapifen can be treated and reversed using a specific opioid antagonist, such as the medication Naloxone, as described in official documents.

Q: How is Rapifen different from morphine?

Official drug information describes Rapifen as having a significantly faster onset and a shorter duration of action compared to morphine. It also describes the potency of Rapifen as being equivalent to approximately 30 times that of oral morphine.

Q: Are there different forms or ways that Rapifen is administered?

The drug is typically supplied as a solution for injection and is administered only as an Intravenous (IV) injection or a continuous IV infusion in the clinical setting.

Q: Can older adults use Rapifen safely?

Official documents note that elderly or debilitated patients are considered to be at an increased risk of severe adverse events, including life-threatening respiratory depression. Official administration instructions state that a reduced initial dose and careful monitoring are needed for this population.

Q: Is it safe to drive or operate machinery after receiving Rapifen?

Official caution advises patients not to drive or operate any tools or machines for at least 24 hours after receiving Rapifen. The medicine can affect a patient's alertness, concentration, and judgment, causing sleepiness or dizziness.

Q: What is known about using Rapifen during pregnancy?

Official information states that prolonged use during pregnancy may cause Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn. For this reason, and others, its use is generally not recommended immediately prior to labor.

Q: Does Rapifen interact with anxiety medications?

The use of Rapifen with certain anxiety medications, especially benzodiazepines, carries a high-level regulatory warning. This combination increases the risk of profound sedation, respiratory depression, coma, and death.

Q: Are there long-term side effects noted for Rapifen?

Official research focuses almost exclusively on short-term effects observed during and immediately after the procedure. Because of this, information on long-term outcomes and effects is not fully established.

Q: Can Rapifen be used if a person has a history of substance use?

Official documents acknowledge that the risk of addiction and misuse is increased in patients with a personal or family history of substance abuse. This history is a factor that healthcare providers must consider when evaluating treatment.

Q: Are there specific medical conditions that prevent the use of Rapifen?

Specific conditions listed as contraindications (reasons the drug must not be used) in official documents include hypersensitivity to the drug, severe respiratory depression, and certain conditions causing increased intracranial pressure.

Q: What type of monitoring is usually done when a patient receives Rapifen?

Because of its potency and associated risks, official instructions state that patients must be continuously monitored for respiratory effects during and after administration. Monitoring typically also includes regular checks of blood pressure and heart rate.

Q: Can people with kidney problems use Rapifen?

Official cautions note that patients with conditions like renal failure may be at an increased risk of respiratory depression. Some sources describe it as an option where no major dose reduction is needed for patients with only kidney impairment, but close observation is always required.

Q: What is the general expectation for pain relief level after Rapifen?

Official research conducted during studies of the drug describes that Rapifen was associated with low post-operative pain scores during the immediate recovery period. This is consistent with its intended use as a potent analgesic during and shortly after a medical procedure.

Q: Does Rapifen affect the ability to concentrate?

Official caution advises that the medicine can make you less alert than usual and can affect your judgment and ability to concentrate. This is the reason why patients are instructed not to drive or operate machinery for a period after receiving the drug.

Q: Is Rapifen used in emergency medical situations?

Rapifen is primarily indicated for use in the perioperative setting. Official documentation also provides an indication for pain relief and sedation in intensive care for adults who are on mechanical ventilation.

Q: Is the name 'Rapifen' used globally, or does it have other brand names?

The active ingredient, alfentanil, is sold under the brand name Rapifen in many countries. It is also known by other brand names in different regions, such as Alfenta in the United States.

Q: What evidence exists regarding Rapifen's use in children's pain management?

Official indications include its use as an opioid analgesic in association with general anesthesia for neonates, infants, children, and adolescents. Research has been conducted to specifically evaluate its performance in these younger patient populations.

Advertisements

How should Rapifen (Fentanyl) be stored and disposed of?

Official Storage and Disposal Requirements

Rapifen (Alfentanil) injection is a highly potent medication that must be stored and handled according to strict regulatory protocols primarily applied in clinical settings.

Storage Conditions

Requirement Specifics
Temperature Store the unopened product at or below 25 C.
Protection Must be kept protected from light and stored in a locked cabinet or controlled drug store.
Container Use The injection is for single use only. Any unused contents from the opened ampoule must be immediately discarded.

Handling and Disposal

Due to its classification, specific handling and disposal rules are mandatory for healthcare personnel. The diluted solution, if not used at once, can be stored refrigerated (2 C to 8 C) for a maximum of 24 hours.

Handling requires personnel to wear gloves; in case of accidental skin contact, the area must be rinsed with water, avoiding soap or alcohol. Disposal of all unused and waste material is the responsibility of the healthcare facility and must strictly follow local pharmaceutical waste regulations for controlled substances.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rapifen (Fentanyl) found in:

A-Z Index: